Pharma Deals Review, Vol 2010, No 5 (2010)

Font Size:  Small  Medium  Large

Novartis and Array Agree MEK Inhibitor Deal Worth up to USD 467 M

Debbie Tranter

Abstract


Novartis has agreed to pay Array BioPharma USD 467 M for worldwide rights to those MEK inhibitors in clinical development, thus strengthening its involvement in the cancer therapeutics arena.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.